論文・技術情報追加のお知らせ

1. Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study.

ズラノロンとブレキサノロンのリアルワールド副作用比較評価。

対象DB：FAERS

2. Disproportionality analysis of sex-stratified adverse event signals in growth impairment: Insights from the FDA adverse event reporting system.

小児成長障害治療薬の性別による副作用シグナル差異の分析。

対象DB：FAERS

3. Assessing the risk of cataracts associated with medications: A pharmacovigilance analysis of the FAERS database.

FAERSデータに基づく薬剤誘発性白内障リスクの総合的分析。

対象DB：FAERS

4. HIV as a Host Susceptibility State for Severe Drug Hypersensitivity: Disentangling Biological Susceptibility from Drug Exposure in the FAERS Database.

HIV感染における重症薬疹発生リスクと薬剤曝露の影響の検証。

対象DB：FAERS

5. Signal mining and analysis of adverse events associated with Isotretinoin: A 20-Year real-world pharmacovigilance study based on FAERS and EudraVigilance databases.

イソトレチノインの副作用に関する20年間の自発報告解析。

対象DB：EudraVigilance,FAERS

6. A genomic-led strategy to anticipate drug safety effects.

創薬初期における医薬品副作用を予測するゲノム主導戦略の開発。

対象DB：FAERS

7. Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review.

循環器領域での副作用検出・予測におけるAI活用の総合レビュー。

対象DB：FAERS,VigiBase

8. Safety of Immune-Targeted Therapy in Patients with Hepatocellular Carcinoma in the Real-World.

肝細胞がんに対する免疫・分子標的併用療法の安全性プロファイル。

対象DB：FAERS

9. Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database.

乳がん治療のCDK4/6阻害薬併用による心血管毒性リスク解析。

対象DB：FAERS

10. Seasonal Variation in Reporting of Venous Thromboembolism in a Spontaneous Adverse Event Reporting System: Analysis of the Japanese Adverse Drug Event Report Database.

JADERを用いた静脈血栓塞栓症副作用報告の季節変動の解析。

対象DB：FAERS,JADER

11. Pharmacovigilance analysis of central nervous system adverse events associated with sevoflurane and drug interactions: a disproportionality study based on the FDA adverse event reporting system (FAERS) database.

セボフルラン麻酔における中枢神経系副作用と相互作用の解析。

対象DB：FAERS

12. Concurrent Insomnia and Suicidal Ideation and Behavior as Psychiatric Adverse Effects of Clozapine Versus Other Atypical Antipsychotics.

クロザピンにおける不眠症と自殺念慮・行動の関連性に関する分析。

対象DB：CVAR,FAERS

13. Real-World Dermatologic Adverse Events of CAR T-Cell Therapy: A Decade-Wide Disproportionality Analysis of the FDA Adverse Event Reporting System.

CAR-T細胞療法に伴う皮膚副作用のFAERS不均衡分析。

対象DB：FAERS

14. Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis using FAERS.

小児と成人における薬剤性急性膵炎リスクの年齢層別シグナル解析。

対象DB：FAERS

15. Immune checkpoint inhibitor-associated eosinophilic fasciitis: A FAERS pharmacovigilance analysis of a rare rheumatic immune-related adverse event.

免疫チェックポイント阻害薬による好酸球性筋膜炎の副作用調査。

対象DB：FAERS

16. Comparative safety profiles of enzalutamide, olaparib, and lutetium Lu-177 vipivotide tetraxetan in patients with prostate cancer: a real-world disproportionality analysis of the FAERS database.

前立腺がん治療薬3種のFAERS不均衡分析による安全性比較。

対象DB：FAERS

17. Muscle toxicity reports in FAERS: a disproportionality analysis with focus on rhabdomyolysis and cross-database assessment.

FAERSを用いた横紋筋融解症等を含む薬剤性筋毒性シグナル評価。

対象DB：FAERS

18. Post-marketing safety of lecanemab: a real-world study based on FAERS database, multicenter cohort and network pharmacology.

アルツハイマー病薬レカネマブの市販後安全性プロファイルの評価。

対象DB：FAERS

19. Comparative safety profile of biktarvy: insights from a clinical cohort and the FAERS database.

ビクタルビ配合剤の安全性に関する臨床コホートとFAERS比較。

対象DB：FAERS

20. Comparison of safety of lecanemab and donanemab: a real-world disproportionality analysis using the FDA adverse event reporting system.

アルツハイマー病薬レカネマブとドナネマブの安全性比較分析。

対象DB：FAERS

21. Pre-existing Comorbidities as Potential Risk Modifiers for New-Onset Myocarditis and Pericarditis following mRNA COVID-19 Vaccination in Males Aged 18-30 in the United States: A Disproportionality Analysis using VAERS Spontaneous Reporting Data.

若年男性のmRNAワクチン後心筋炎リスクと併存疾患の関連分析。

対象DB：FAERS,VAERS

22. Analysis of immune checkpoint inhibitor-associated Stevens-Johnson syndrome/toxic epidermal necrolysis using the FAERS and OpenVigil databases.

免疫チェックポイント阻害薬によるSJS/TENの副作用解析。

対象DB：FAERS

23. Abnormal dreams and night terrors with atogepant: A case series.

アトゲパント投与に伴う異常夢・夜驚症のケースシリーズ研究。

対象DB：FAERS

24. Reported safety events from ultrasound enhancing agents: a critical reappraisal.

FAERSにおける超音波造影剤の重篤な有害事象報告傾向の評価。

対象DB：FAERS

25. Urinary tract infections, urosepsis, and multiple sclerosis disease modifying therapies: a disproportionality analysis of the FDA Adverse Event Reporting System.

多発性硬化症修飾療法と尿路感染症・尿路性敗血症リスクの解析。

対象DB：FAERS

26. Prediction and mechanistic insights into drug-induced reproductive toxicity through integrated machine learning, FAERS-based signal comparison, and network toxicology analyses.

機械学習等を統合した薬剤性生殖毒性の予測とメカニズム解明。

対象DB：FAERS

27. Post-marketing safety analysis of nafamostat: A retrospective pharmacovigilance study using the Japanese Adverse Drug Event Report (JADER) database.

JADERデータを用いたナファモスタットの市販後安全性評価。

対象DB：JADER

28. Avacopan-Associated Hepatobiliary Adverse Events and Vanishing Bile Duct Syndrome: A PMDA/JADER and FAERS Reporting-Profile Comparison.

アバコパンに伴う肝胆道障害と消退性胆管症候群の評価・比較。

対象DB：JADER

29. Roles of myeloperoxidase and the AMPK/PI3K/AKT/eNOS pathway in osimertinib-induced cardiotoxicity: multilevel evidence from disequilibrium analysis, network pharmacology, mendelian randomization, and animal experiments.

オシメルチニブ誘発性心毒性のメカニズムと多角的な証拠の検証。

対象DB：VigiBase

30. Association between SGLT2 inhibitors and reporting of phimosis/paraphimosis: a comparative pharmacovigilance analysis of the WHO database.

WHOデータに基づくSGLT2阻害薬と包茎関連有害事象の分析。

対象DB：VigiBase

31. Functional impairment in patients undergoing major orthopaedic surgery under general anaesthesia with or without regional anaesthesia: a target trial emulation using a national hospital claims database.

整形外科手術における全身＋神経ブロック麻酔の日常動作改善効果。

対象DB：DPC

32. Hospital Budget Impact and Provider-Side Economic Evaluation of Lecanemab and Donanemab Under Japan's National Fee Schedule: A Head-to-Head Linear Model.

日本の診療報酬制度下でのレカネマブ・ドナネマブ経済性評価。

対象DB：DPC

33. Machine learning-based prediction of hospital-associated complications after tibial fracture surgery in older patients: a nationwide Japanese database study.

高齢者脛骨骨折手術後の院内合併症を予測する機械学習モデル開発。

対象DB：DPC

34. Age- and sex-based risk stratification in takotsubo syndrome: a Japanese nationwide registry study.

たこつぼ心筋症における年齢・性別に応じたリスク層別化と予後。

対象DB：DPC

35. Trends in ritodrine prescriptions among pregnant women in Japan: a nationwide descriptive analysis of an administrative hospital database from 2015 to 2024.

日本における妊婦へのリトドリン処方動向の全国レセプト調査。

対象DB：DPC

36. Long-term medical support after definitive surgery for esophageal atresia: analysis using a national inpatient database in Japan.

食道閉鎖症根治術後の長期在宅医療要否の全国データベース解析。

対象DB：DPC

37. Increased performance of thoracoscopic, mediastinoscopic, and robotic esophageal cancer surgeries in Japan: a decade-long nationwide claims-based analysis (2014-2023).

日本の食道がんに対する低侵襲・ロボット手術の10年間の推移。

対象DB：NDB

38. Trends in Diagnosing Obesity: The CALOR Study.

肥満診断の有無による高BMI患者の特性と経時的傾向の調査。

対象DB：MDV

39. Psychiatric prescribing patterns in patients with newly diagnosed bipolar disorder in the UK: 2000 to 2022.

英国の新規双極性障害患者における精神科薬処方パターンの遷移。

対象DB：CPRD

40. Childbirth Acquired Perineal Trauma (CHAPTER) study: A cohort study investigating health outcomes after childbirth-related perineal trauma.

分娩時会陰損傷の頻度と精神・身体的転帰への影響に関する研究。

対象DB：CPRD

41. Approaches to handling missing ethnicity data in primary care data research in England and Wales: a systematic review of methods.

英国プライマリケア研究における民族性欠損データの処理方法検討。

対象DB：CPRD

42. Weight loss prior to diagnosis of first-episode psychosis predicts subsequent weight gain: a retrospective cohort study of the UK Clinical Practice Research Datalink (CPRD) primary care database.

初発統合失調症診断前の体重減少と発症後体重増加予測の関連性。

対象DB：CPRD

43. Natural history of hypochondroplasia: A retrospective, matched-cohort study using the clinical practice research Datalink (CPRD) aurum database.

軟骨無形成類似症の自然経過に関する英国CPRD対照研究。

対象DB：CPRD

44. Risk of fracture with gabapentinoid treatment in older adults: a multinational population-based study.

高齢者におけるガバペンチノイド処方と骨折リスクの多国籍調査。

対象DB：CPRD

45. Epidemiology of idiopathic inflammatory myopathies: a population-based cohort in England, 2002-2021.

イングランドにおける特発性炎症性筋疾患の疫学と臨床経過の評価。

対象DB：CPRD

46. Identifying the determinants of hospital readmission in dementia patients - A retrospective cohort study using electronic healthcare records in England.

認知症患者の再入院に関わる要因の電子カルテデータによる同定。

対象DB：CPRD

47. Evaluating bias in target trial emulation for heart failure across statistical and deep learning methods.

心不全の標的臨床試験エミュレーションにおけるバイアス評価。

対象DB：CPRD

48. Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records.

本態性高血圧症に対するラミプリル/インダパミド併用療法の評価。

対象DB：THIN

49. Gastrointestinal adverse reactions and metabolism-nutrition disorders associated with hypomethylating agents: a pharmacovigilance study with exploratory mechanistic analysis.

低脱メチル化製剤に伴う消化器・代謝栄養障害の不均衡分析と考察。

対象DB：CVAR

50. Prediction model for aortic dissection, aortic aneurysm, and peripheral artery disease.

健診データを用いた大動脈解離・大動脈瘤等のリスク予測モデル。

対象DB：DeSC

51. Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists After Bowel Obstruction or Ileus: A Nationwide, Real-World, Database Study.

腸閉塞発症後のGLP-1受容体作動薬の中止頻度・要因調査。

対象DB：DeSC

52. Effectiveness of Metformin in Preventing Colorectal Cancer Among Japanese Patients With Type 2 Diabetes: A Target Trial Emulation.

日本人2型糖尿病患者におけるメトホルミンの大腸がん予防効果。

対象DB：DeSC